Aimmune Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2011-01-01
- Employees
- 275
- Market Cap
- -
- Website
- http://www.aimmune.com
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
Phase 2
Completed
- Conditions
- Peanut Allergy
- Interventions
- Biological: Placebo powder provided in capsulesBiological: AR101 powder provided in capsules
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Aimmune Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01987817
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸UC San Diego, San Diego, California, United States
© Copyright 2025. All Rights Reserved by MedPath